Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Piperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DNM1 | Q05193 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL6685072 | 1.00 | HIF1A (0.43) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL27879283 | 0.85 | HIF1A (0.50) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL791431 | 0.85 | — | — | |
| Piperazine SCHEMBL27476631 | 0.84 | DNM1 (0.50) | HIF1AMAPTPDE4AKDRDNM1 | |
| Piperidine SCHEMBL7523716 | 0.84 | ALDH1A1 (0.53) | CXCR4SMN1; SMN2DNM1MEN1KMT2A | |
| Piperazine SCHEMBL13281519 | 0.82 | DNM1 (0.63) | DNM1MEN1KMT2AALDH1A1TSHR | |
| Piperazine SCHEMBL28328748 | 0.81 | HIF1A (0.46) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL2842298 | 0.81 | HIF1A (0.55) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL14739784 | 0.81 | HIF1A (0.55) | HIF1AMAPTPDE4AKDRCXCR4 | |
| Piperazine SCHEMBL5946683 | 0.81 | HIF1A (0.55) | HIF1AMAPTPDE4AKDRCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101274901-B | Synthetic method for (E)-3-aryl-2-acrylic amide compound | UNIV ZHEJIANG | 2010-06-23 | — | — | CN | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| CN-101274901-A | Synthetic method for (E)-3-aryl-2-acrylic amide compound | UNIV ZHEJIANG (CN) | 2008-10-01 | — | — | CN | disclosed |
| EP-1856099-A2 | ACRIDINE AND QUINOLINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-1314660-C | Cinnamide compound synthesizing process | UNIV ZHEJIANG (CN) | 2007-05-09 | — | — | CN | disclosed |
| WO-2006094237-A2 | ACRIDINE AND QUINOLINE DERVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| CN-1740145-A | Cinnamide compound synthesizing process | UNIV ZHEJIANG (CN) | 2006-03-01 | — | — | CN | disclosed |
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | HIF1A 1362/4885MAPT 4135/4885PDE4A 602/4885 |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | HIF1A 1363/4885MAPT 207/4885PDE4A 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.